Pharma Focus America

Pendopharm Signs Exclusive Agreement to Distribute Ascendis Pharma A/S's TransCon™ PTH in Canada

Friday, July 05, 2024

Pendopharm, a division of Pharmascience Inc., has announced an exclusive distribution agreement with Ascendis Pharma A/S (NASDAQ: ASND), a biopharmaceutical company based in Copenhagen, Denmark. Under this agreement, Pendopharm will handle regulatory approval and commercialization of Ascendis' TransConTM PTH (palopegteriparatide) in Canada, aimed at treating chronic hypoparathyroidism. Financial terms of the deal were not disclosed.

TransConTM PTH, marketed as YORVIPATH® in the EU, EEA, and Great Britain, is designed to replace parathyroid hormone (PTH) for patients suffering from insufficient PTH levels. It represents an advancement beyond standard treatments involving oral calcium and active vitamin D. The therapy has already been approved in Europe and is undergoing development for approval in the United States, Japan, and other global markets.

Dr. Aliya Khan, a prominent Canadian Parathyroidologist, highlighted the significance of TransConTM PTH as the first approved treatment option for chronic hypoparathyroidism in Canada. She emphasized its potential to enhance quality of life and reduce serious health risks associated with the condition.

Pendopharm, expressed excitement about the partnership's role in bringing innovative healthcare solutions to Canadians. Ascendis Pharma's Executive Vice President and Chief Commercial Officer, Camilla Harder Hartvig, underscored their joint commitment to improving patient outcomes through this collaboration.

The agreement underscores Pharmascience's strategic goal of expanding its presence in the life sciences sector by introducing transformative therapies like TransConTM PTH. Martin Arès, CEO of Pharmascience, reiterated their dedication to advancing patient access to innovative medicines globally.

TransConTM PTH acts as a prodrug of PTH 1-34, administered once daily to maintain physiological PTH levels throughout the day. It has received regulatory approval in Europe and is currently under review by the FDA in the US, with a PDUFA date set for August 14, 2024. Development efforts also extend to Japan and China, highlighting its potential global impact.

Hypoparathyroidism, caused by insufficient PTH levels, poses significant health risks including neuromuscular issues, renal complications, and cognitive impairments. Surgical procedures account for most cases, although autoimmune and genetic factors also contribute to its prevalence.

This partnership between Pendopharm and Ascendis Pharma underscores a joint effort to address critical medical needs and improve patient outcomes through innovative pharmaceutical solutions.

 

Source: newswire.ca

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024